Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 3087-3095

  Santos, José Ramón ^a,b   Blanco, José Luis ^c,o   Masiá, Mar ^d,e,p   Gutiérrez, Félix ^d,e,p   Pérez Elías, María Jesús ^f   Iribarren, José Antonio ^g   Force, Lluis ^h,q   Antela, Antonio ⁱ   Knobel, Hernando ^j   Salavert, Miguel ^k   De Quirós, Juan Carlos López Bernaldo ^l   Pino, María ^a,m   Paredes, Roger ^a,m,n   Clotet, Bonaventura ^a,b,m,n   Bravo, Isabel ^a   Martínez Picado, Javier ^a   Rojas, John F ^o   Gatell, José M ^o   Díaz, Alberto ^f   Gutiérrez, Carolina ^f   Galán, Juan Carlos ^f   Moreno, Santiago ^f   Ibarguren, Maialen ^g   Barrufet, Pilar ^q   Losada, Elena ⁱ   Aguilera, Antonio ⁱ   Gonzalez, Alicia ^j   Molina, José Miguel ^k   Carrero, Ana ^l   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Elche University Hospital   (Spain)

^e MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h Mataro Hospital   (Spain)

ⁱ University Hospital of Santiago de Compostela   (Spain)

^j HOSPITAL DEL MAR   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m AIDS Research Institute IrsiCaixa HIVACAT   (Spain)

ⁿ UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^o HOSPITAL CLÍNIC   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^q HOSPITAL DE MATARÓ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EMTRICITABINE; INTEGRASE; LAMIVUDINE; RALTEGRAVIR; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; GENE DOSAGE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PREVALENCE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SPAIN; TERTIARY CARE CENTER; TREATMENT WITHDRAWAL; VIREMIA; VIRUS INHIBITION; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; ISOLATION AND PURIFICATION; MULTICENTER STUDY; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; PREVALENCE; RALTEGRAVIR POTASSIUM; RETROSPECTIVE STUDIES; SPAIN; TERTIARY CARE CENTERS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84948977402     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv205     Document Type: Article

References (39)

1. Rockstroh JK, DeJesus E, Lennox JL et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013; 63: 77-85.
2. Rockstroh JK, Lennox JL, Dejesus E et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53: 807-16.
3. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
4. Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50: 605-12.
5. Yazdanpanah Y, Fagard C, Descamps D et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49: 1441-9.
6. European AIDS Clinical Society (EACS). Guidelines, Version 7.1, November 2014. http://www.eacsociety.org/files/guidelines-7.1-english.pdf.
7. FDA. FDA Approves New Combination Pill for HIV Treatment for Some Patients. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm317004.htm.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services, 2015. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
9. DeJesus E, Rockstroh JK, Henry K et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
10. Sax PE, DeJesus E, Mills A et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
11. Clotet B, Feinberg J, van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 6736: 1-10.
12. Eron JJ, Clotet B, Durant J et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 2013; 207: 740-8.
13. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210: 354-62.
14. Goethals O, Clayton R, Van Ginderen M et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82: 10366-74.
15. Abram ME, Hluhanich RM, Goodman DD et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013; 57: 2654-63.
16. Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther 2011; 16: 137-40.
17. Hatano H, Lampiris H, Fransen S et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54: 389-93.
18. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
19. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
20. Geretti A, Fearnhill E, Ceccherini-Silberstein F et al. Prevalence and patterns of raltegravir resistance in treated patients in Europe [abstract]. Antivir Ther 2010; 15: A62.
21. Malet I, Gimferrer Arriaga L, Artese A et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother 2014; 69: 2118-22.
22. Canducci F, Ceresola ER, Boeri E et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011; 204: 1811-5.
23. Vavro C, Huang J, Underwood M et al. Integrase genotypic and phenotypic predictors of antiviral response to dolutegravir (DTG) in subjects with resistance to integrase inhibitors (INIs). In: Abstracts of the International Workshop on HIV&Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, ON, 2013. Abstract 29, p. 37. University of California, San Diego School Medicine, La Jolla, CA, USA.
24. Hurt CB, Sebastian J, Hicks CB et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014; 58: 423-31.
25. Young B, Fransen S, Greenberg KS et al. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011; 16: 253-6.
26. Boyd SD, Maldarelli F, Sereti I et al. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther 2011; 16: 257-61.
27. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 2012; 308: 387-402.
28. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42: 1608-18.
29. Nichols G, Lazzarin A, Maggiolo F et al. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily (BID) in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 subjects enrolled. In: Abstracts of the Seventh IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, 2013. Abstract TULBPE19. International AIDS Society, Geneva, Switzerland.
30. Team RDC. R: A Language and Environment for Statistical Computing. 2010. http://www.r-project.org.
31. Lennox JL, Dejesus E, Berger DS et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39-48.
32. Eron JJ, Rockstroh JK, Reynes J et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, activecontrolled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11: 907-15.
33. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-32.
34. Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97.
35. Sax PE, Tierney C, Collier AC et al. Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230-40.
36. Smith KY, Patel P, Fine D et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23: 1547-56.
37. Van Leth F, Andrews S, Grinsztejn B et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19: 463-71.
38. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007; 4: 11.
39. Montarroyos UR, Miranda-Filho DB, César CC et al. Factors related to changes in CD4+ T-cell counts over time in patients living with HIV/AIDS: a multilevel analysis. PLoS One 2014; 9: e84276.